NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Fresenius Medical Care AG & Co. KGAA (NYSE: FMS) resulting from allegations that Fresenius may have issued materially misleading business information to the investing public.
On January 6, 2017, after the close of trading, the Wall Street Journal published an article revealing that Fresenius’s U.S. unit had received subpoenas from federal prosecutors seeking information on Fresenius’s ties with the American Kidney Fund, a charity that helps patients pay for kidney dialysis. On this news, shares of Fresenius have fallen approximately 7% during intraday trading on January 9, 2017.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Fresenius investors. If you purchased shares of Fresenius before January 9, 2017 please visit the firm’s website at http://www.rosenlegal.com/cases-1027.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.